• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. — EBioMedicine

Sep 1, 2022 | Publications

Click here to view...

A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned — BiorXiv

Aug 9, 2022 | Publications

Click here to view...

Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. — EBioMedicine

Jul 27, 2022 | Publications

Click here to view...

Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. — Nature Scientific Reports

Jul 8, 2022 | Publications

Click here to view...

Vaccine Researchers Face Unique Challenges in Updating New Covid Boosters

Apr 18, 2022 | Publications

Click here to view...
Next Entries »

Recent Posts

  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
  • Institutional Biosafety Committee
  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow